Articles in Peer Reviewed Journals:
1. A. Bukreyev, E. Camargo, and P. Collins. Recovery of infectious respiratory syncytial virus expressing an additional, foreign gene
(1996). J. Virol. 70:6634-6641.
2. A. Bukreyev, S. Whitehead, B. Murphy, and P. Collins (1997). Recombinant respiratory syncytial virus from which the entire SH gene has
been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. J. Virol.
3. B. Beer, R. Kurth, and A. Bukreyev (1999). Characteristics of Filoviridae: Marburg and Ebola Viruses. Review article. Natur Wissenschaften 86:8-17.
4. A. Bukreyev, S. S. Whitehead, N. Bukreyeva, B. R. Murphy, and P. L. Collins (1999). Interferon gamma expressed by a recombinant
respiratory syncytial virus attenuates virus replication and yet maintains immunogenicity in mice. Proc. Natl. Acad. Sci. USA 96:2367-2372.
5. S. S. Whitehead, A. Bukreyev, M. N. Teng, C.-Y. Firestone, M. St. Clair, W. R. Elkins, P. L. Collins, and B. R. Murphy (1999).
Recombinant respiratory syncytial virus (RSV) bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. J. Virol.
6. P. L. Collins, S. S. Whitehead, A. Bukreyev, R. Fearns, M. N. Teng, K. Juhasz, R. M. Chanock, and B. M. Murphy (1999). Rational design
of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics. Review. In: Advances in virus research,
54:423-451. Academic Press.
7. A. Bukreyev, S. S. Whitehead, C. Prussin, B. R. Murphy and P. L. Collins (2000). Effect of co-expression of IL-2 by recombinant
respiratory syncytial virus on virus replication, immunogenicity and production of other cytokines. J. Virol. 74:7151-7157.
8. A. Bukreyev, B. R. Murphy, and P. L. Collins (2000). Respiratory syncytial virus can tolerate an intergenic sequence of at least 160
nucleotides with little effect on transcription or replication in vitro and in vivo. J. Virol. 74:11017-11026.
9. A. Bukreyev, I. M. Belyakov, J. A. Berzofsky, B. R. Murphy and P. L. Collins (2001). Granulocyte-macrophage colony-stimulating factor
expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells. J. Virol. 75:12128-12140.
10. A. Bukreyev and I. Belyakov (2002). Expression of immunomodulating molecules by recombinant viruses: Can the immunogenicity of live
virus vaccines be improved? Review article. Expert Rev. Vaccines 1(2):233-245.
11. A. Bukreyev, M. H. Skiadopoulos, J. McAuliffe, B. R. Murphy, P. L. Collins and A. C. Schmidt (2002). More antibody with less antigen:
Can immunogenicity of attenuated live virus vaccines be improved? Proc. Natl. Acad. Sci. USA 99:16987-16991. The article was chosen for PNAS press
release on 12/09/02.
12. A. Kotelkin, E. A. Prikhod'ko, J. I. Cohen, P. L. Collins and A. Bukreyev (2003). Respiratory Syncytial Virus Infection Sensitizes
Cells to Apoptosis Mediated by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL). J. Virol. 77:9156-9172.
13. H. Bisht, A. Roberts, L. Vogel, A. Bukreyev, P. Collins, B. Murphy, K. Subbarao, and B. Moss (2004). SARS coronavirus spike protein
expressed by a highly attenuated recombinant vaccinia virus induces neutralizing antibody and protectively immunizes mice. Proc. Natl. Acad. Sci. USA 101(17):6641-6646.
14. A. Bukreyev, E. W. Lamirande, U. J. Buchholz, L. N. Vogel, W. R. Elkins, M. St. Clair, B. R. Murphy, K. Subbarao, and P. L. Collins
(2004). Mucosal immunization protects monkeys against SARS coronavirus infection. Lancet. 363(9427):2122-2127. The article was chosen for Lancet press release on 06/23/04 and the NIH press release on 06/24/04.
15. U. J Buchholz, A. Bukreyev, L. Yang, E. W. Lamirande, B. R. Murphy, K. Subbarao, and P. L Collins (2004). Contributions of the
structural proteins of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) to protective immunity. Proc. Natl. Acad. Sci. USA.
16. L. Zhang, A. Bukreyev, C. Thompson, B. Watson, M. E. Peeples, P. L Collins, and R. J. Pickles (2005). Infection of ciliated cells by
parainfluenza virus type 3 in an vitro model of human airway epithelium. J. Virol. 79:1113-1124.
17. A. Bukreyev, I. M. Belyakov, G. A. Prince, K. C. Yim, K. K. Harris, J. A. Berzofsky, and P. L. Collins (2005). Expression of
interleukin-4 by recombinant respiratory syncytial virus is associated with accelerated inflammation and a non-functional cytotoxic T lymphocyte response
following primary infection but not following challenge with wild-type virus. J. Virol. 79:9515-9526. The article was chosen for J. Virol. spotlight.
18. A. Bukreyev, Z. Huang, L. Yang, S. Elankumaran, M. St. Claire, B. R. Murphy, S. K. Samal, and P. L. Collins (2005). Recombinant
Newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. J. Virol. 79: 13275-13284.
19. A. Bukreyev, L. Yang, S. R. Zaki, W-J. Shieh, P. E. Rollin,B. R. Murphy, P. L. Collins, and A. Sanchez (2006). A single intranasal inoculation with a paramyxovirus-vectored
vaccine protects guinea pigs against a lethal dose Ebola virus challenge. J. Virol. 80:2267-2279.
20. A. Bukreyev, M. E. Serra, F. R. Laham, S. R. Kleeberger, P. L. Collins, and F. P. Polack (2006). The cysteine-rich region and secreted
form of the attachment G glycoprotein of respiratory syncytial virus enhance the cytotoxic T lymphocyte response despite lacking MHC class I-restricted
epitopes. J. Virol. 80:5854-5861. The article was chosen for J. Virol. spotlight.
21. A. Kotelkin, I. M. Belyakov, L. Yang, J. A. Berzofsky, P. L. Collins, and A. Bukreyev (2006). The NS2 protein of human respiratory
syncytial virus suppresses the cytotoxic T cell response as a consequence of suppressing the type I interferon response. J. Virol 80:5958-5967.
22. A. Bukreyev, M. H. Skiadopoulos, B. R. Murphy, and P. L. Collins. (2006). Nonsegmented negative-strand viruses as vaccine vectors.
Review. J. Virol. 80:10293-10306.
23. A. Bukreyev, P. E. Rollin, M. Tate, L. Yang, S. R. Zaki, W.-J. Shieh, B. R. Murphy, P. L. Collins, and A. Sanchez (2007). Successful
topical respiratory tract immunization of primates against Ebola virus. J. Virol. 81:6379-6388.
24. J. DiNapoli, A. Kotelkin, L. Yang, B. R. Murphy, S. Samal, P. L. Collins, and A. Bukreyev (2007). Newcastle disease virus, a host
range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proc. Natl. Acad. Sci. USA 104(23):9788-9793 .
25. J. M. DiNapoli, L. Yang, A. Suguitan Jr., S. Elankumaran, B. R. Murphy, S. K. Samal, P. L. Collins, and A. Bukreyev (2007).
Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces high titer serum neutralizing antibodies against
highly pathogenic avian influenza virus. J. Virol. 81(21):11560-11568. The article was chosen for American Society for Microbiology press release
in November 2007.
26. J. Harker, A. Bukreyev, P. Collins, B. Wang, J. S. Tregoning, and P. J. M. Openshaw (2007). Virally delivered cytokines alter the
immune response to future lung infections. J. Virol. 81(32):13105-13111.
27. P. L. Collins and A. Bukreyev (2007). Advances in the development of vaccines against Marburg and Ebola viruses. Review. Future Medicine: Future Virology 2 (6):537-541.
28. A. Bukreyev and P. Collins (2008). Newcastle disease virus as a vaccine vector for humans. Review. Current Opinion in Molecular Therapeutics 10(1):46-55.
29. J. H. Kuhn. and C. H. Calisher (2008). Filoviridae: The Marburgviruses and Ebolaviruses. Springer, ISBN 3-211-20671-X. A contributor.
30. L. Yang, A. Sanchez, P. E. Rollin, B. R. Murphy, P. L. Collins, and A. Bukreyev (2008). The HPIV3-vectored intranasal
vaccine against Ebola virus is immunogenic in HPIV3-immune animals. Virology 377 (2):255-264.
31. S. Munir, C. Luongo, C. Le Nouen, U. J. Buchholz, P. L. Collins, and A. Bukreyev (2008). Non-structural proteins
1 and 2 of respiratory syncytial virus suppress maturation of human dendritic cells. J. Virol. 82 (17):8780-8796.
32. P. L. Collins, A. Bukreyev, and B. R. Murphy (2008). What are the risks - hypothetical and observed - of recombination involving live
vaccines and vaccine vectors based on nonsegmented negative strand RNA viruses? J. Virol 82 (19):9805-9806.
33. A. Bukreyev, L. Yang, J. Fricke, L. Cheng, J. M. Ward, B. R. Murphy, and P. L. Collins (2008). The secreted form of the G glycoprotein
of respiratory syncytial virus helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects of Fc
receptor-bearing leucocytes. J. Virol. 82 (24):12191-12204.
34. J. M. DiNapoli, B. R. Murphy, P. L. Collins, and A. Bukreyev (2008). Impairment of the CD8+ T cell response in lungs following
respiratory versus non-respiratory viral infections. Virology Journal 5:105.
35. A. Bukreyev, A. Marzi, F. Feldmann, L. Zhang, L. Yang, J. M. Ward, D. Dorward, R. J. Pickles, B. R. Murphy, H. Feldmann, and P. L.
Collins (2009). Chimeric respiratory paramyxovirus bearing Ebola glycoprotein as a sole envelope protein for prevention of Ebola virus infection. Virology, 383 (2):348-361.
36. C. Le Nouën S. Munir, S. Losq, C. C Winter, T. McCarty, D. A Stephany, K. L Holmes, A. Bukreyev, R. L. Rabin, P. L Collins, and
U. J Buchholz (2009). Infection and maturation of monocyte-derived human dendritic cells by human respiratory syncytial virus, human metapneumovirus, and
human parainfluenza virus type 3. Virology, 385 (1):169-182.
37. J. M. DiNapoli, J. M. Ward, L. Yang, S. Elankumaran, B. R. Murphy, S. K. Samal, P. L. Collins, and A. Bukreyev (2009) . Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended
for humans. Vaccine, 27 (10):1530-1539.
38. J. DiNapoli, B. Nayak, L. Yang, B. W. Finneyfrock, A. Cook, H. Anderson, F. Torres-Velez, B. Murphy, S. Samal, P. Collins, and A. Bukreyev (2010). Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly
pathogenic avian influenza virus protect against virus challenge in monkeys. J. Virol. 84 (3):1489-1503.
39. A. Bukreyev and P. Collins (2010). Filovirus vaccines: what challenges are left? Expert Review of Vaccines, 9 (1):5-8.
40. A. Bukreyev, L. Yang, B. Murphy, and P. Collins (2010). Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in
the respiratory tract of vector-immune monkeys and is immunogenic. Virology 399 (2):290-298.
41. J. Harker, A. Godlee, J. L. Walhsten, D. C. P. Lee, L. Thorne, D. Sawant, J. S. Tregoning, R. Caspi, A. Bukreyev, P. L. Collins, and
P. J. M. Openshaw (2010). Interleukin 18 co-expression during respiratory syncytial virus infection results in enhanced disease mediated by natural killer
cells. J. Virol. 84 (8):4073-4082.
42. J. A. Harker, D. C. P. Lee, Y. Yamaguchi, B. Wang, A. Bukreyev, P. L. Collins, J. S. Tregoning, and P. J. M. Openshaw. (2010). The
delivery of cytokines by recombinant virus in early life alters the immune response to adult lung infection. J. Virol. 84(10):5294-5302. The
article was chosen for J. Virol. spotlight.
43. C. Le Nouën, P. Hillyer, S. Munir, C. C Winter, T. McCarty, A. Bukreyev, P. L Collins, R. L Rabin, and U. J Buchholz (2010).
Effects of human respiratory syncytial virus, metapneumovirus, paramyxovirus type 3, and influenza A virus on the ability of human dendritic cells to
activate autologous CD4 T cells. PLoS One 5(11):e15017.
44. S. Netesov, S. Wagener, A. Bukreyev, L. Kolombet, D. Pobedimskaya, R. Hawley, I. Belyakov, Y. Remnev, E. Turin (2010). English-Russian
Harmonized Dictionary of Biological Safety and Security. Non-commercial Partnership "Center of Modern Medical Technologies TEMPO".
45. J. DiNapoli, S. Samal, P. Collins, and A. Bukreyev (2010). Respiratory tract immunization of primates with a Newcastle disease
virus-vectored vaccine induces neutralizing antibody response against Ebola virus. Vaccine 29:17-25.
46. S. Munir, P. Hillyer, C. Le Nouën, U. J. Buchholz, R. Rabin, P. Collins, and A. Bukreyev (2011). Respiratory syncytial virus
interferon antagonist NS1 protein suppresses and skews the T lymphocyte response. PLoS Pathogens 7(4):e1001336.
47. M. L. Hastie, M. J. Headlam, N. B. Patel, A. A. Bukreyev, U. J. Buchholz, K. A. Dave, E. L. Norris, C. L. Wright, K. M. Spann, P. L.
Collins and J. J. Gorman (2012). The human respiratory syncytial virus non-structural protein 1 regulates type I and type II interferon pathways. Mol. Cell. Proteomics. 11(5):108-127.
48. A. Bukreyev, L. Yang, and P. Collins (2012). The secreted G protein of human respiratory syncytial virus (RSV) antagonizes
antibody-mediated restriction of replication involving macrophages and complement. J. Virol. 86(19):10880-10884.
49. J. S. Tregoning, B.L. Wang, J. U. McDonald, Y. Yamaguchi, J. A. Harker, M. Goritska, C. Johansson, A. Bukreyev, P. Collins, and P. J.
Openshaw (2013). Neonatal antibody responses are attenuated by interferon gamma produced by CD8 and NK cells during RSV infection (2013). Proc. Natl. Acad. Sci. USA 110(14):5576-5581.
50. N. M. Lubaki, P. Ilinykh, C. Pietzsch, B. Tigabu, A. N. Freiberg, R. A. Koup, and A. Bukreyev (2013). The lack of maturation of Ebola
virus-infected dendritic cells results from the cooperative effect of at least two viral domains. J. Virol. 87(13):7471-7485. The article was
chosen for UTMB press release on 05/02/13.
51. P. A. Ilinykh, B. Tigabu, A. Ivanov, T. Ammosova, Y. Obukhov, T. Garron, N. Kumari, D. Kovalskyy, M. O. Platonov, V. S. Naumchik, A. N. Freiberg, S. Nekhai, and A. Bukreyev (2014). Role of protein phosphatase 1 in dephosphorylation of Ebola
virus VP30 and its targeting for the inhibition of viral transcription. J Biol. Chem. 289(33): 22723-38.
52. K. A. Dave, E. L. Norris, A. A. Bukreyev, M. J. Headlam, U. J. Buchholz, T. Singh, P. L. Collins and J. J. Gorman. (2014) A
comprehensive proteomic view of responses of A549 cells to human respiratory syncytial virus infection. Mol. Cell. Proteomics. MCP M114.041129.
53. A. I. Flyak, P. A. Ilinykh, C. D. Murin, T. Garron, X. Shen, M. L. Fusco, T. Hashiguchi, Z. A. Bornholdt, J. C. Slaughter, G. Sapparapu, T. G. Ksiazek,
A. B. Ward, E. O. Saphire, A. Bukreyev*, and J. E. Crowe, Jr.* (2015) Mechanism of human antibody-mediated neutralization of
Marburg virus. Cell 160(5) 893-903. The article was chosen for UTMB and the Vanderbilt University press releases on 5/26/2015. *Co-senior authors.
54. P. Ilinykh, M. Lubaki, S. Widen, L. A. Renn, T. C. Theisen, N. R. Rabin, T. Wood, and A. Bukreyev. (2015) Different temporal effects
of Ebola virus VP35 and VP24 on global gene expression in human dendritic cells. J. Virol. 90(15):7567-83.
55. M. Meyer, T. Garron, N. M. Lubaki, C. E. Mire, K. A. Fenton, C. Klages, G. G. Olinger, T. W.
Geisbert, P. L. Collins, and A. Bukreyev. (2015) Aerosolized Ebola vaccine protects primates and elicits
lung-resident T-cell responses. J. Clin. Invest. 125(8): 3241-55. The article was chosen for UTMB press release and NIH press release on
56. R. F. Russell, J. U. McDonald, M. Ivanova, Z. Zhong, A. Bukreyev, J. S. Tregoning. (2015) The partial attenuation of Small Hydrophobic
(SH) gene deleted RSV is associated with elevated IL-1β responses. J. Virol. 89(17): 8974-81.
57. M. Edwards, C. Pietzsch, T. Thibaut; M. Shaw, A. Bukreyev, C. Basler. (2015) High-throughput minigenome system for identifying small
molecule inhibitors of Ebola virus replication. ACS Infectious Diseases 1(8): 380-387.
58. A. I. Flyak, X. Shen, C. D. Murin, H. L. Turner, M. L. Fusco, R. Lampley, N. Kose, P. A. Ilinykh, N. Kuzmina, A. Branchizio, H. King, L. Brown, C.
Bryan, E. Davidson, B. J. Doranz, J. C. Slaughter, G. Sapparapu, C. Klages, T. G. Ksiazek, E. O. Saphire, A. B. Ward, A. Bukreyev,* and J. E. Crowe, Jr. (2016) Cross-reactive and potent neutralizing antibody responses in human survivors of natural
Ebolavirus infection. Cell 164(3): 392-405. The article was chosen for UTMB and the Vanderbilt University press releases on
1/21/2016, and was highlighted in Nature 529, 440. *Co-corresponding author.
59. P. A. Ilinykh, Xiaoli Shen, A. I. Flyak, N. Kuzmina, T. G. Ksiazek, J. E. Crowe, Jr., A. Bukreyev. (2016) Chimeric
filoviruses for identification and characterization of monoclonal antibodies. J. Virol. 90(8): 3890-901.
60. A. Rialdi, L. Campisi, N. Zhao, A. C. Lagda, C. Pietzsch, J. S. Ho, L. Martinez-Gil, R. Fenouil, X. Chen, M. Edwards, G. Metreveli, S. Jordan, Z.
Peralta, C. Muniz-Fontela, N. Bouvier, M. Merad, J. Jin, M. Weirauch, S. Heinz, C. Benner, H. van Bakel, C. Basler, A. Garcia-Sastre,A. Bukreyev, and I. Marazzi. (2016) Topoisomerase 1 inhibition suppresses inflammatory genes and protects from death by inflammation. Science. Epub on Apr 28, 2016. The article was chosen for Icahn School of Medicine at Mount Sinai press releases on 4/28/2016.
61. N. M. Lubaki, P. Younan, R. I. Santos, M. Meyer,
M. Iampietro, R. A. Koup, and A. Bukreyev. (2016). The Ebola interferon inhibiting
domains attenuate and dysregulate cell-mediated immune responses. PLOS Pathogens 21(12):e1006031. The article was chosen for UTMB
press releases on 12/01/2016.
62. I. V. Kuzmin, T. M. Schwarz, P. A. Ilinykh, I. Jordan, T. G. Ksiazek,
R. Sachidanandam, C. F. Basler, and A. Bukreyev (2017).
Innate immune response of bat and human cells to filoviruses: commonalities
and distinctions. J. Virol. 91(8):e02471-16.
64. P. Younan, P. Ramanathan, J. Graber, F. Gusovsky, and A. Bukreyev. (2017). The TLR4 antagonist Eritoran protects
mice from lethal filovirus challenge. mBio 8(2) e00226-17.
65. M. Iampietro, P. Younan, A. Nishida, M. Dutta, N.
M. Lubaki, R. I. Santos, R. A. Koup, M. G.
Katze, and A. Bukreyev. (2017). Ebola virus
glycoprotein directly triggers T lymphocyte death despite of the lack of
infection. PLOS Pathogens 13(5):e1006397. The article was chosen
for UTMB press releases on 05/24/2017.
66. P. Younan, M. Iampietro, A. Nishida, P.
Ramanathan, R. I. Santos, M. Dutta, N. M. Lubaki, R.
A. Koup, M. G. Katze, and A. Bukreyev. (2017). Ebola binding to Tim-1 on
T-Lymphocytes induces a cytokine storm. mBio in press